Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.64 |
| ▸ | RAB9A | P51151 | 3/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.48 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.47 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.46 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.44 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.44 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.44 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7423800 | 1.00 | NPC1 (0.64) | NPC1RAB9AL3MBTL1SMN1; SMN2GAA | |
| SCHEMBL24325183 | 0.87 | NPC1 (0.68) | NPC1RAB9AL3MBTL1SMN1; SMN2GAA | |
| SCHEMBL8566008 | 0.86 | NPC1 (0.62) | NPC1RAB9AL3MBTL1SMN1; SMN2GAA | |
| SCHEMBL17619538 | 0.86 | NPC1 (0.62) | NPC1RAB9AL3MBTL1SMN1; SMN2GAA | |
| SCHEMBL7424161 | 0.86 | NPC1 (0.62) | NPC1RAB9AL3MBTL1SMN1; SMN2GAA | |
| SCHEMBL8560198 | 0.86 | NPC1 (0.62) | NPC1RAB9AL3MBTL1SMN1; SMN2GAA | |
| SCHEMBL7422992 | 0.85 | NPC1 (0.61) | NPC1RAB9AL3MBTL1SMN1; SMN2GAA | |
| SCHEMBL8566435 | 0.85 | NPC1 (0.61) | NPC1RAB9AL3MBTL1SMN1; SMN2GAA | |
| SCHEMBL7422983 | 0.85 | NPC1 (0.61) | NPC1RAB9AL3MBTL1SMN1; SMN2GAA | |
| SCHEMBL8566501 | 0.84 | NPC1 (0.60) | NPC1RAB9AL3MBTL1SMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170291890-A1 | HETEROCYCLE SUBSTITUTED AMINO-PYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | Epizyme, Inc. | 2017-10-12 | — | — | US | disclosed |
| US-20170291890-A1 | HETEROCYCLE SUBSTITUTED AMINO-PYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | Epizyme, Inc. | 2017-10-12 | — | — | US | disclosed |
| EP-0815103-A1 | TRYPSIN AND THROMBIN INHIBITORS | Novartis AG (CH) | 1998-01-07 | — | — | EP | disclosed |
| WO-1996029327-A1 | TRYPSIN AND THROMBIN INHIBITORS | NOVARTIS AG (CH) | 1996-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170291890-A1 | HETEROCYCLE SUBSTITUTED AMINO-PYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | HCCS, TP53, NME2 | NPC1 2481/4885RAB9A 1803/4885L3MBTL1 4229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.